Latest Atlas Venture Life Science Advisors, LLC Stock Portfolio
$1.08Billion– No. of Holdings #16
Atlas Venture Life Science Advisors, LLC Performance:
2024 Q1: 30.37%YTD: 30.37%2023: -20.23%
Performance for 2024 Q1 is 30.37%, and YTD is 30.37%, and 2023 is -20.23%.
About Atlas Venture Life Science Advisors, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Atlas Venture Life Science Advisors, LLC reported an equity portfolio of $1.1 Billions as of 31 Mar, 2024.
The top stock holdings of Atlas Venture Life Science Advisors, LLC are DYN, KYMR, . The fund has invested 21% of it's portfolio in DYNE THERAPEUTICS, INC. and 20% of portfolio in KYMERA THERAPEUTICS, INC.
The fund managers got completely rid off AKERO THERAPEUTICS, INC. (AKRO) stocks. They significantly reduced their stock positions in XILIO THERAPEUTICS, INC. (XLO), SPERO THERAPEUTICS, INC. (SPRO) and DIANTHUS THERAPEUTICS, INC.. Atlas Venture Life Science Advisors, LLC opened new stock positions in Q32 BIO, INC..
The top stock holdings of Atlas Venture Life Science Advisors, LLC are DYN, KYMR, . The fund has invested 21% of it's portfolio in DYNE THERAPEUTICS, INC. and 20% of portfolio in KYMERA THERAPEUTICS, INC.
The fund managers got completely rid off AKERO THERAPEUTICS, INC. (AKRO) stocks. They significantly reduced their stock positions in XILIO THERAPEUTICS, INC. (XLO), SPERO THERAPEUTICS, INC. (SPRO) and DIANTHUS THERAPEUTICS, INC.. Atlas Venture Life Science Advisors, LLC opened new stock positions in Q32 BIO, INC..
Atlas Venture Life Science Advisors, LLC Equity Portfolio Value
Last Reported on: 06 May, 2024
Atlas Venture Life Science Advisors, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Atlas Venture Life Science Advisors, LLC made a return of 30.37% in the last quarter. In trailing 12 months, it's portfolio return was 16.37%.
New Buys
| Ticker | $ Bought |
|---|---|
| q32 bio, inc. | 35,649,500 |
New stocks bought by Atlas Venture Life Science Advisors, LLC
Additions
Reductions
| Ticker | % Reduced |
|---|---|
| xilio therapeutics, inc. | -64.02 |
| spero therapeutics, inc. | -40.04 |
| dianthus therapeutics, inc. | -21.1 |
| dyne therapeutics, inc. | -18.87 |
| day one biopharmaceuticals, inc. | -15.48 |
| disc medicine, inc. | -10.49 |
| kymera therapeutics, inc. | -8.21 |
Atlas Venture Life Science Advisors, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| akero therapeutics, inc. | -8,388,510 |
Atlas Venture Life Science Advisors, LLC got rid off the above stocks
Sector Distribution
Atlas Venture Life Science Advisors, LLC has about 73.8% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 73.8 |
| Others | 26.2 |
Market Cap. Distribution
Atlas Venture Life Science Advisors, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 46.4 |
| UNALLOCATED | 26.2 |
| MID-CAP | 21 |
| MICRO-CAP | 6.2 |
Stocks belong to which Index?
About 73% of the stocks held by Atlas Venture Life Science Advisors, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 73 |
| Others | 27 |
Atlas Venture Life Science Advisors, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Atlas Venture Life Science Advisors, LLC
Atlas Venture Life Science Advisors, LLC has 16 stocks in it's portfolio. About 96.5% of the portfolio is in top 10 stocks. THRD proved to be the most loss making stock for the portfolio. DYN was the most profitable stock for Atlas Venture Life Science Advisors, LLC last quarter.
Last Reported on: 06 May, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AKRO | akero therapeutics, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVRO | avrobio, inc. | 0.54 | 4,541,380 | 5,812,970 | unchanged | 0.00 | ||
| AVTE | aerovate therapeutics, inc. | 5.57 | 2,039,250 | 60,300,600 | unchanged | 0.00 | ||
| DAWN | day one biopharmaceuticals, inc. | 9.80 | 6,430,260 | 106,228,000 | reduced | -15.48 | ||
| DYN | dyne therapeutics, inc. | 21.01 | 8,020,140 | 227,692,000 | reduced | -18.87 | ||
| GBIO | generation bio, co. | 3.11 | 8,279,480 | 33,697,500 | unchanged | 0.00 | ||
| IKNA | ikena oncology, inc. | 0.66 | 5,018,180 | 7,125,810 | unchanged | 0.00 | ||
| KYMR | kymera therapeutics, inc. | 19.95 | 5,377,360 | 216,170,000 | reduced | -8.21 | ||
| REPL | replimune group, inc. | 1.58 | 2,098,300 | 17,143,100 | unchanged | 0.00 | ||
| SPRO | spero therapeutics, inc. | 0.10 | 607,613 | 1,045,090 | reduced | -40.04 | ||
| THRD | third harmonic bio, inc. | 9.50 | 10,907,900 | 102,970,000 | unchanged | 0.00 | ||
| VIGL | vigil neuroscience, inc. | 1.84 | 5,836,870 | 19,903,700 | unchanged | 0.00 | ||
| XLO | xilio therapeutics, inc. | 0.10 | 992,912 | 1,072,340 | reduced | -64.02 | ||
| disc medicine, inc. | 13.14 | 2,287,230 | 142,403,000 | reduced | -10.49 | |||
| korro bio, inc. | 9.30 | 1,119,290 | 100,736,000 | unchanged | 0.00 | |||
| q32 bio, inc. | 3.29 | 2,092,110 | 35,649,500 | new | ||||
| dianthus therapeutics, inc. | 0.52 | 186,979 | 5,609,370 | reduced | -21.1 | |||